-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, March 12, recently, Huadong Medicine acquired a 100% stake in HighTechnology Products, SLU, a Spanish energy-source medical and aesthetic equipment company, with a consideration of 65 million euros and a sales milestone payment of up to 20 million euros
.
Acquired 4 international companies in
three years andcompleted the international layout in the field of medical beauty.
In
recent years, Huadong Medicine 's layout in the field of medical beauty has continued to expand
.
According to Huadong Medicine, the company's medical beauty business focuses on the research and development, production and sales of the latest products and devices in the fields of facial micro-plastic surgery and skin management
.
The current key medical beauty products and projects include hyaluronic acid, thread embedding, collagen stimulant, botulinum toxin, and freezing freckle removal equipment
.
Huadong Medicine's layout in the field of medical aesthetics dates back to 2013, when the company won the exclusive agency rights of South Korea's LG company's Yiwan brand hyaluronic acid in China
.
According to the data released by Frost&Sullivan, the market share of the Yiwan brand in the domestic hyaluronic acid field is currently the largest.
This shows that Huadong Medicine has strong sales and operation capabilities in the domestic medical aesthetics field
.
In November 2018, Huadong Medicine acquired Sinclair, a British listed company, for US$220 million, officially opening the path of forward-looking global expansion of the medical aesthetics business, and made non-surgical medical aesthetics products the core area of the company's key development
.
Since then, in April 2019, Huadong Medicine participated in R2 Medical Technology Co.
, Ltd.
, invested 20 million US dollars, and its shareholding ratio was 26.
60%
.
At the same time, the company obtained the exclusive distribution rights of F1 and F2, a frozen freckle removal medical device developed by R2, and their future improvements in 34 Asian countries or regions including China, Japan, and South Korea.
Huadong Medical Beauty began to enter energy source medicine.
U.
S.
equipment market
.
In 2020, Sinclair, a wholly-owned subsidiary of Huadong Medicine in the UK, has successively signed the global commercial rights of MaiLi high-end hyaluronic acid with Kylane Laboratoires SA; won the exclusive agency rights of South Korean JETEMA's botulinum toxin products in China; invested 6 million euros and received the transfer Kylane became its third largest shareholder with 20% equity, and locked in advance the IP (intellectual property) of Kylane's two key research and development products in the field of facial and body fillers and its global rights and interests
.
It took less than 3 years for Huadong Medicine to complete the entire industrial chain layout of the international medical aesthetics business.
It currently has 4 global R&D centers, 5 global production bases, and nearly 20 high-end market products targeting Full coverage of non-surgical products
.
The 360 billion Chinese medical cosmetology market
has broad prospects for the development of the medical cosmetology business.
Huadong Medicine is fully deploying its business in the medical cosmetology field.
The reason is the continuous growth of the Chinese medical cosmetology market
.
According to ISAPS data, the global medical aesthetics market in 2019 was RMB 958.
6 billion, with a compound growth rate of 8.
3% from 2013 to 2019, of which the global non-surgical medical aesthetics market accounted for 54.
5%
.
According to Frost&Sullivan statistics, the scale of China's medical aesthetics market is RMB 176.
9 billion, with a compound growth rate of 22.
5% from 2014 to 2019.
It is expected to surpass the United States in 2021 and become the world's largest medical aesthetics market, reaching 360.
13 billion yuan in 2023.
.
Among them, the market share of non-surgical items will increase to 45.
3% in 2024, and non-surgical items are expected to become the main driver of China's medical aesthetics market
.
In addition, Frost&Sullivan statistics show that the penetration rate of medical beauty in mainland China increased from 1.
5% to 3.
6% in 2019, but it still has a large gap compared with major countries in the world, about 1/3 of Japan, 1/5 of the United States, and South Korea.
1/6, the penetration rate of my country's medical beauty consumption is expected to continue to grow, and the domestic medical beauty market is in a stage of rapid development
.
Huadong Medicine's 2019 annual report shows that during the reporting period, the company's annual revenue was 35.
446 billion yuan, and the international medical beauty business achieved a revenue of 509 million yuan
.
It is worth mentioning that the company's 2020 performance forecast shows that the net profit attributable to shareholders of listed companies is 2.
8 to 3 billion yuan, a year-on-year increase of only 0%-7%.
Among them, the overall loss of medical beauty business is mainly considered as the subsidiary Sinclair The sale of the distribution rights of related products in the Western Europe region was 30.
65 million pounds (after-tax income)
.
Huadong Medicine stated that in the future, the company will continue to focus on the high-end global medical aesthetics market, and regard the Chinese market as a special market for the company's medical aesthetics business, and gradually introduce world-class products with high technological content into the country, and strive to become a world-class medical aesthetics enterprise.
.
.
Acquired 4 international companies in
three years andcompleted the international layout in the field of medical beauty.
In
recent years, Huadong Medicine 's layout in the field of medical beauty has continued to expand
.
According to Huadong Medicine, the company's medical beauty business focuses on the research and development, production and sales of the latest products and devices in the fields of facial micro-plastic surgery and skin management
.
The current key medical beauty products and projects include hyaluronic acid, thread embedding, collagen stimulant, botulinum toxin, and freezing freckle removal equipment
.
Huadong Medicine's layout in the field of medical aesthetics dates back to 2013, when the company won the exclusive agency rights of South Korea's LG company's Yiwan brand hyaluronic acid in China
.
According to the data released by Frost&Sullivan, the market share of the Yiwan brand in the domestic hyaluronic acid field is currently the largest.
This shows that Huadong Medicine has strong sales and operation capabilities in the domestic medical aesthetics field
.
In November 2018, Huadong Medicine acquired Sinclair, a British listed company, for US$220 million, officially opening the path of forward-looking global expansion of the medical aesthetics business, and made non-surgical medical aesthetics products the core area of the company's key development
.
Since then, in April 2019, Huadong Medicine participated in R2 Medical Technology Co.
, Ltd.
, invested 20 million US dollars, and its shareholding ratio was 26.
60%
.
At the same time, the company obtained the exclusive distribution rights of F1 and F2, a frozen freckle removal medical device developed by R2, and their future improvements in 34 Asian countries or regions including China, Japan, and South Korea.
Huadong Medical Beauty began to enter energy source medicine.
U.
S.
equipment market
.
In 2020, Sinclair, a wholly-owned subsidiary of Huadong Medicine in the UK, has successively signed the global commercial rights of MaiLi high-end hyaluronic acid with Kylane Laboratoires SA; won the exclusive agency rights of South Korean JETEMA's botulinum toxin products in China; invested 6 million euros and received the transfer Kylane became its third largest shareholder with 20% equity, and locked in advance the IP (intellectual property) of Kylane's two key research and development products in the field of facial and body fillers and its global rights and interests
.
It took less than 3 years for Huadong Medicine to complete the entire industrial chain layout of the international medical aesthetics business.
It currently has 4 global R&D centers, 5 global production bases, and nearly 20 high-end market products targeting Full coverage of non-surgical products
.
The 360 billion Chinese medical cosmetology market
has broad prospects for the development of the medical cosmetology business.
Huadong Medicine is fully deploying its business in the medical cosmetology field.
The reason is the continuous growth of the Chinese medical cosmetology market
.
According to ISAPS data, the global medical aesthetics market in 2019 was RMB 958.
6 billion, with a compound growth rate of 8.
3% from 2013 to 2019, of which the global non-surgical medical aesthetics market accounted for 54.
5%
.
According to Frost&Sullivan statistics, the scale of China's medical aesthetics market is RMB 176.
9 billion, with a compound growth rate of 22.
5% from 2014 to 2019.
It is expected to surpass the United States in 2021 and become the world's largest medical aesthetics market, reaching 360.
13 billion yuan in 2023.
.
Among them, the market share of non-surgical items will increase to 45.
3% in 2024, and non-surgical items are expected to become the main driver of China's medical aesthetics market
.
In addition, Frost&Sullivan statistics show that the penetration rate of medical beauty in mainland China increased from 1.
5% to 3.
6% in 2019, but it still has a large gap compared with major countries in the world, about 1/3 of Japan, 1/5 of the United States, and South Korea.
1/6, the penetration rate of my country's medical beauty consumption is expected to continue to grow, and the domestic medical beauty market is in a stage of rapid development
.
Huadong Medicine's 2019 annual report shows that during the reporting period, the company's annual revenue was 35.
446 billion yuan, and the international medical beauty business achieved a revenue of 509 million yuan
.
It is worth mentioning that the company's 2020 performance forecast shows that the net profit attributable to shareholders of listed companies is 2.
8 to 3 billion yuan, a year-on-year increase of only 0%-7%.
Among them, the overall loss of medical beauty business is mainly considered as the subsidiary Sinclair The sale of the distribution rights of related products in the Western Europe region was 30.
65 million pounds (after-tax income)
.
Huadong Medicine stated that in the future, the company will continue to focus on the high-end global medical aesthetics market, and regard the Chinese market as a special market for the company's medical aesthetics business, and gradually introduce world-class products with high technological content into the country, and strive to become a world-class medical aesthetics enterprise.
.
